Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Mar 19;12(3):ofaf034.
doi: 10.1093/ofid/ofaf034. eCollection 2025 Mar.

Long-term Safety and Effectiveness of Rezafungin Treatment in Candidemia and Invasive Candidiasis: Results From an Early Access Program in Italy and Germany

Filippo Trapani  1   2 , Giulio Viceconte  3 , Valentina Morena  4 , Giusy Tiseo  5 , Giovanni Mori  6   7 , Britta Kölking  8 , Elham Khatamzas  8   9
Affiliations
Clinical Trial

Long-term Safety and Effectiveness of Rezafungin Treatment in Candidemia and Invasive Candidiasis: Results From an Early Access Program in Italy and Germany

Filippo Trapani et al. Open Forum Infect Dis. .

Abstract

Outcomes are reported for 6 adults receiving rezafungin for chronic, hard-to-treat, invasive candidiasis (including Candida parapsilosis) during an early access program. Rezafungin was well tolerated and administered via once-weekly outpatient intravenous infusion for up to 39 weeks during the program, enabling hospital discharge and replacing daily antifungal infusions.

Keywords: candidemia; early access program; echinocandin; invasive candidiasis; rezafungin.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. Filippo Trapani, Giulio Viceconte, Valentina Morena, Giovanni Mori, Elham Khatamzas, and Britta Kölking have no relevant financial disclosures. Giusy Tiseo received speaker honoraria for educational meetings by Shionogi and honoraria for participation in a scientific advisory board by MSD. The study was funded by Mundipharma Research Limited.

Figures

Figure 1.
Figure 1.
Computed tomography scan images for Case 6 at diagnosis and at 8 months after starting treatment with echinocandin including rezafungin, showing regression of prevertebral soft tissue swelling. The patient required lifelong antifungal therapy and continued rezafungin treatment after the early access program period (ongoing at 19 months). A, T2 sagittal image of the cervical spine. B, Contrast media subtraction images.
See this image and copyright information in PMC

References

    1. Wolfgruber S, Sedik S, Klingspor L, et al. Insights from three pan-European multicentre studies on invasive Candida infections and outlook to ECMM Candida IV. Mycopathologia 2024; 189:70. - PMC - PubMed
    1. Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases—estimate precision. J Fungi 2017; 3:57. - PMC - PubMed
    1. Koehler P, Stecher M, Cornely OA, et al. Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis. Clin Microbiol Infectn 2019; 25:1200–12. - PubMed
    1. Perlin DS. Echinocandin resistance in Candida. Clin Infect Dis 2015; 61:S612–7. - PMC - PubMed
    1. Pristov KE, Ghannoum MA. Resistance of Candida to azoles and echinocandins worldwide. Clin Microbiol Infect 2019; 25:792–8. - PubMed

Publication types